用于多发性骨髓瘤的靶向BCMA疗法：2024年美国血液学会年会的最新进展
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.
作者信息
Zheng Huijian, Xian Huajian, Zhang Wenjie, Lu Chaoqun, Pan Renyao, Liu Han, Xu Zhenshu
机构信息
Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Rd, Fuzhou, 350001, China.
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, National Research Center for Translational Medicine at Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
出版信息
J Hematol Oncol. 2025 Mar 1;18(1):23. doi: 10.1186/s13045-025-01675-5.
B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.
B细胞成熟抗原（BCMA）目前是多发性骨髓瘤（MM）研究最为广泛的靶点。针对BCMA的疗法，如抗体药物偶联物（ADC）、双特异性抗体（BsAbs）、嵌合抗原受体T细胞（CAR-T）在MM治疗中展现出了良好的前景。我们总结了2024年美国血液学会（ASH）年会关于MM这三类药物的最新报道。
Zotero 插件